Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Vor Biopharma (NASDAQ:VOR) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also weighed in on VOR. Wedbush upped their price objective on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday. Jefferies Financial Group assumed coverage on shares of Vor Biopharma in a research report on Monday, March 30th. They set a “buy” rating and a $50.00 target price on the stock. Citigroup began coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, TD Cowen started coverage on shares of Vor Biopharma in a research note on Wednesday, December 17th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.67.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $18.05 on Friday. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The stock has a market capitalization of $881.74 million, a price-to-earnings ratio of -0.05 and a beta of 1.92. The stock has a fifty day simple moving average of $14.22 and a two-hundred day simple moving average of $17.63.

Institutional Trading of Vor Biopharma

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Vor Biopharma in the 4th quarter worth approximately $36,000. Bank of America Corp DE boosted its stake in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after acquiring an additional 4,144 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the third quarter valued at approximately $230,000. BNP Paribas Financial Markets grew its holdings in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in Vor Biopharma in the third quarter worth $304,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).